(PharmaNewsWire.Com, October 26, 2017 ) According to Publisher, the Global Smart Inhalers market is accounted for $5.8 million in 2015 and is expected to reach $198 million by 2022 growing at a CAGR of 65.5% from 2015 to 2022. Increasing respiratory disorders, rise in air pollution, improved adherence to the inhaler are some of the factors boosting the market growth. However, lesser availability of smart inhalers, high expenditure of asthma and COPD treatment, and resistance towards adoption of smart inhalers are hindering the market growth.
North America is projected to be the leading revenue generating region, whereas Asia-Pacific is projected to grow at the highest rate, due to rise in demand for smart inhalers and increase in COPD and asthma instances. Some of the key players in global Smart Inhalers market are Propeller Health, Glenmark Pharmaceuticals, Qualcomm Life, Opko Health, Adherium Limited, GlaxoSmithKline plc, Novartis AG, AstraZeneca plc , Boehringer Ingelheim GmbH, 3M Drug Delivery Systems, Sensirion AG, Novartis AG, CoheroHealth, Crux Product Design Ltd, e-pill, LLC, Vectura Group plc, Teva Pharmaceutical Industries Ltd., OMRON Healthcare Europe B.V, Shenzhen Bi-Rich Medical Devices Co., Ltd, Inspiro Medical Ltd, TRI-MED, INC., PARI GmbH and Philips Respironics.
Regions Covered: - North America o US o Canada o Mexico - Europe o Germany o France o Italy o UK o Spain o Rest of Europe - Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific - Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: